Is Xospata Approved for FLT3-Positive AML?
Yes, Xospata (gilteritinib) is FDA-approved specifically for adults with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations, confirmed by an FDA-approved test.[1] It targets FLT3 mutations, which occur in about 30% of AML cases and drive aggressive disease.
How Does Xospata Work Against FLT3 Mutations?
Xospata is a tyrosine kinase inhibitor that blocks FLT3 receptor signaling, halting cancer cell growth and survival. It also inhibits other kinases like AXL. In the phase 3 ADMIRAL trial, it showed superior overall survival (9.3 months) versus salvage chemotherapy (5.6 months) in relapsed/refractory FLT3-mutated AML patients.[1][2]
Testing for FLT3 Status Before Treatment
Patients need molecular testing (e.g., PCR or next-generation sequencing) to confirm FLT3-ITD or TKD mutations. The FDA-cleared LeukoStrat test is commonly used. Treatment proceeds only if positive; Xospata is not indicated for FLT3 wild-type AML.[1]
Who Makes Xospata and What's the Dosing?
Astellas Pharma manufactures Xospata. Standard dosing is 120 mg orally once daily until toxicity or disease progression, with food restrictions (taken without food).[1]
When Does Xospata's Patent Protection End?
Key U.S. patents for gilteritinib expire between 2027 and 2032, covering the compound and method of use. Challenges from generics could accelerate entry; check DrugPatentWatch.com for litigation updates.[3]
Common Side Effects and Patient Risks
Fatigue, edema, fever, rash, and diarrhea occur in over 20% of patients. Serious risks include differentiation syndrome (12%), posterior reversible encephalopathy syndrome (<1%), and QT prolongation. Monitor liver function and electrolytes closely.[1]
How Does It Compare to Other FLT3 Inhibitors?
| Drug | Key Trial Survival | Dosing | Notes |
|------|-------------------|--------|-------|
| Xospata (gilteritinib) | OS 9.3 mo (ADMIRAL) | Oral daily | Broad FLT3 coverage; approved monotherapy |
| Quizartinib (Vanflyta) | OS 31.9 mo (QuANTUM-3) | Oral daily w/ chemo | ITD-specific; frontline + chemo |
| Midostaurin (Rydapt) | EFS benefit (RATIFY) | Oral w/ chemo | Frontline combo only |
Xospata excels in relapsed settings; quizartinib targets newly diagnosed ITD-positive AML.[2][4]
Sources:
[1]: FDA Label for Xospata
[2]: NEJM: ADMIRAL Trial
[3]: DrugPatentWatch: Gilteritinib Patents
[4]: FDA: Vanflyta Approval